carbon-monoxide-therapy-neurodegeneration

📖 Wiki Page

therapeutic1974 wordssynced 2026-04-02

Carbon Monoxide (CO) Releasing Compound Therapy for Neurodegeneration

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">carbon-monoxide-therapy-neurodegeneration</th>
</tr>
<tr>
<td class="label">Enzyme</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">HO-1</td>
<td>HMOX1</td>
</tr>
<tr>
<td class="label">HO-2</td>
<td>HMOX2</td>
</tr>
<tr>
<td class="label">CORM</td>
<td>Class</td>
</tr>
<tr>
<td class="label">CORM-2</td>
<td>Ruthenium carbonyl</td>
</tr>
<tr>
<td class="label">CORM-3</td>
<td>Ruthenium carbonyl</td>
</tr>
<tr>
<td class="label">CORM-401</td>
<td>Manganese carbonyl</td>
</tr>
<tr>
<td class="label">ALF-186</td>
<td>Metal carbonyl</td>
</tr>
<tr>
<td class="label">ALF-494</td>
<td>Iron carbonyl</td>
</tr>
<tr>
<td class="label">DI-1</td>
<td>Photoactivatable</td>
</tr>
<tr>
<td class="label">CORM</td>
<td>Company/Group</td>
</tr>
<tr>
<td class="label">CORM-2</td>
<td>Academic groups</td>
</tr>
<tr>
<td class="label">CORM-3</td>
<td>Academic groups</td>
</tr>
<tr>
<td class="label">CORM-401</td>
<td>Academic groups</td>
</tr>
<tr>
<td class="label">ALF-494</td>
<td>Academic groups</td>
</tr>
<tr>
<td class="label">Primary targets</td>
<td>HO-1, CO sensors</td>
</tr>
<tr>
<td class="label">BBB penetration</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">**Clinical

...

Carbon Monoxide (CO) Releasing Compound Therapy for Neurodegeneration

Overview

Carbon monoxide (CO) releasing compound therapy represents an emerging neuroprotective approach for neurodegenerative diseases that exploits the endogenous gasotransmitter's anti-inflammatory, anti-apoptotic, and mitochondrial protection properties. CO is one of three primary gasotransmitters in the human body (alongside nitric oxide [NO] and hydrogen sulfide [H₂S]) and plays crucial roles in cellular signaling, mitochondrial function, and stress response[@corm_neuro_2023].

The therapeutic potential of CO-releasing molecules (CORMs) spans multiple neurodegenerative conditions including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis), and [Huntington's disease](/diseases/huntingtons-disease). Unlike exogenous CO gas administration, CORMs deliver controlled amounts of CO to achieve therapeutic effects without toxicity[@co_brain_2024].

The CO Gasotransmitter System {#co-system}

Endogenous CO Production

CO is produced endogenously through heme oxygenase (HO) enzyme-mediated degradation of heme:

Heme + O₂ + NADPH → Biliverdin + CO + Fe²⁺ + NADP⁺

Two HO isoforms exist with distinct physiological roles:

HO-1 (also known as HSP32) is highly inducible by oxidative stress, heat shock, inflammatory stimuli, and hypoxia. Its upregulation represents a conserved cellular protective response. HO-2 is constitutively expressed in neurons and maintains baseline CO production for physiological signaling[@ho1_neuro_2023].

CO as a Neuroprotective Agent

CO exerts multiple protective effects in the nervous system:

Mermaid diagram (expand to render)

CO-Releasing Molecule (CORM) Compounds {#corm-compounds}

CORMs are designed to release CO in a controlled manner, avoiding the toxicity associated with high CO concentrations. Several classes have been developed:

CORM-2

CORM-2 (dicobalt octacarbonyl) was one of the first CORMs developed:

Mechanism: Releases CO upon exposure to light or certain chemical conditions.

Advantages:

Well-characterized release kinetics
Widely used in preclinical studies
Good stability in organic solvents

Limitations:

Requires light activation for controlled release
Cobalt component may cause toxicity
Limited water solubility

CORM-2 has demonstrated neuroprotective effects in multiple models, including reduction of infarct size in stroke models and protection against β-amyloid toxicity[@corm_neuro_2023].

CORM-3

CORM-3 (tricarbonylchloro(glycinato)ruthenium(II)) is a water-soluble CORM:

Advantages:

Water-soluble, can be administered in aqueous solutions
Faster CO release than CORM-2
More physiologically relevant

Limitations:

Short half-life (~3 minutes)
Rapid CO release may cause tissue-specific effects

CORM-3 has shown particular promise in PD models, protecting dopaminergic neurons from 6-OHDA and MPTP toxicity[@corm_pd_2023].

CORM-401

CORM-401 is a mitochondria-targeted CORM:

Mechanism:

Triphenylphosphonium cation drives accumulation in mitochondria (ΔΨm-dependent)
CO released specifically within the mitochondrial matrix
Directly targets mitochondrial CO signaling pathways

Advantages:

Mitochondria-specific delivery
Potent at low concentrations
Protects against mitochondrial dysfunction

Limitations:

Requires intact mitochondrial membrane potential
More complex chemistry

CORM-401 has shown efficacy in models where mitochondrial dysfunction is central, including PD and ALS[@co_mito_2023].

ALF-494

ALF-494 is a novel iron-based CORM:

Advantages:

Iron-based (more biocompatible than ruthenium)
Moderate release kinetics
Reduced metal toxicity

Limitations:

Earlier development stage
Less characterization data

ALF-494 represents the next generation of CORMs with improved safety profiles.

Neuroprotective Mechanisms {#mechanisms}

Anti-Inflammatory Effects

CO modulates neuroinflammation through multiple pathways:

p38 MAPK Pathway: CO activates p38 MAPK signaling, which suppresses pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6) while promoting anti-inflammatory mediators (IL-10)[@corm_neuro_2023].

NF-κB Inhibition: CO inhibits NF-κB nuclear translocation, reducing expression of inflammatory genes. This effect is mediated through activation of p38 MAPK and upregulation of HO-1.

Microglial Modulation: CO shifts microglial activation from pro-inflammatory (M1) to anti-inflammatory (M2) phenotype, promoting tissue repair and reducing chronic neuroinflammation.

Anti-Apoptotic Signaling

CO protects neurons from apoptotic cell death through:

Bcl-2 Family: CO upregulates anti-apoptotic Bcl-2 and Bcl-xL while inhibiting pro-apoptotic Bax translocation to mitochondria[@corm_apoptosis_2022].

Caspase Inhibition: CO inhibits caspase-3 activation through the MAPK pathway, blocking the execution phase of apoptosis.

Akt Pathway: CO activates PI3K/Akt signaling, which promotes neuronal survival through phosphorylation of BAD and activation of downstream effectors.

Antioxidant Effects

The HO-1/CO system creates a beneficial antioxidant response:

HO-1 Induction: CO itself induces HO-1 expression, creating a positive feedback loop for antioxidant protection[@ho1_neuro_2023].

Ferritin Sequestration: While heme degradation releases iron (potentially pro-oxidant), this is rapidly sequestered by ferritin, which is also induced by CO. This coupling ensures antioxidant benefits outweigh pro-oxidant effects.

Nrf2 Activation: CO activates Nrf2 (Nuclear factor erythroid 2-related factor 2), the master regulator of antioxidant response genes, leading to upregulation of HO-1, NQO1, GCLM, and other antioxidant enzymes[@co_nrf2_2024].

Mitochondrial Protection

CO preserves mitochondrial function through:

Membrane Potential: CO preserves mitochondrial membrane potential (ΔΨm) and inhibits mitochondrial permeability transition pore (mPTP) opening[@co_mito_2023].

Complex IV: CO binds to cytochrome c oxidase (Complex IV), modulating its activity in a protective manner at low concentrations.

PGC-1α: CO promotes mitochondrial biogenesis through PGC-1α (PPARGC1A) activation, supporting generation of new healthy mitochondria.

Autophagy Induction

CO induces autophagy through:

mTOR Inhibition: CO inhibits mTORC1 signaling, relieving inhibition of autophagy initiation[@co_autophagy_2024].

LC3 Conversion: CO promotes LC3-I to LC3-II conversion, enhancing autophagosome formation.

Aggregate Clearance: CO-induced autophagy may enhance clearance of toxic protein aggregates including amyloid-β, tau, and α-synuclein.

Therapeutic Applications by Disease {#disease-applications}

Alzheimer's Disease {#alzheimers-disease}

CO deficiency has been documented in AD patients, with reduced HO-1 activity and CO levels in the brain. CORM therapy addresses multiple hallmarks of AD pathology:

Amyloid pathology: CORMs reduce amyloid-β aggregation and toxicity through:

Direct interaction with Aβ to prevent oligomerization
Enhanced microglial phagocytosis via Nrf2 activation
Reduced BACE1 expression and amyloid precursor protein processing

Tau pathology: CO modulates tau phosphorylation through:

Inhibition of GSK-3β activity
Reduced CDK5 activation
Enhanced protein phosphatase 2A activity

Synaptic dysfunction: CO enhances synaptic plasticity:

Promotion of long-term potentiation (LTP)
NMDA receptor modulation
Increased synaptophysin expression

Mitochondrial function: CO improves energy metabolism:

Preservation of complex IV activity
ATP production maintenance
Reduction of mitochondrial ROS

Mermaid diagram (expand to render)

Preclinical evidence: In 5xFAD and APP/PS1 mice, CORM-3 treatment reduced cortical amyloid plaque burden, improved performance in Morris water maze, and preserved hippocampal synaptic density["@corm_ad_2022"].

Parkinson's Disease {#parkinsons-disease}

Mitochondrial dysfunction is central to PD pathogenesis, making CORMs particularly relevant:

Dopaminergic neuron protection: CORMs protect against:

6-Hydroxydopamine (6-OHDA) toxicity
MPTP-induced parkinsonism
α-Synuclein-induced neurodegeneration

Mitochondrial quality control: CORMs enhance:

Mitophagy induction via PINK1/Parkin pathway
Mitochondrial biogenesis (PGC-1α activation)
Complex I activity preservation

Neuroinflammation: CORMs modulate:

Microglial activation state (M1 to M2 shift)
TNF-α and IL-1β reduction
NLRP3 inflammasome inhibition

α-Synuclein pathology: CORMs may reduce:

α-Synuclein aggregation
Phosphorylation at Ser129
Oligomer formation

Preclinical evidence: In MPTP-treated mice and 6-OHDA-lesioned rats, CORM-3 protected dopaminergic neurons, improved behavioral scores, and preserved striatal dopamine content[@corm_pd_2023].

Amyotrophic Lateral Sclerosis {#als}

ALS involves multiple pathological mechanisms that CORMs can address:

Motor neuron protection: CORMs have shown:

Protection against excitotoxicity
Preservation of neuromuscular junctions
Reduced oxidative stress in motor neurons

Glial modulation: CORMs affect:

Astrocyte reactivity reduction
Microglial modulation
Oligodendrocyte support

SOD1 models: In SOD1-G93A transgenic mice:

CORM-2 delayed disease progression
CORM-3 reduced motor neuron loss
Combination with riluzole showed synergy[@corm_als_2024]

Energy metabolism: CORMs support:

Mitochondrial function in skeletal muscle
Motor endplate maintenance
Metabolic adaptation

Huntington's Disease {#huntingtons-disease}

CO plays roles in HD through several mechanisms:

Mitochondrial dysfunction: CO improves:

Complex I-IV activity in striatal neurons
ATP production in affected brain regions
Mitochondrial dynamics (fusion/fission balance)

Transcriptional dysregulation: CO modulates:

Nrf2-mediated antioxidant response
HSF1 activation and heat shock protein expression
CBP activity in transcriptional regulation

Excitotoxicity: CO protects against:

NMDA-mediated excitotoxicity
Metabolic compromise
Calcium dysregulation

Autophagy: CO enhances:

Autophagic clearance of mutant huntingtin
mTOR-independent autophagy pathways
Lysosomal function

Clinical Development Status {#clinical-status}

As of 2026, CORM therapy for neurodegeneration remains in preclinical development:

Challenges to clinical translation:

Optimal dosing: CO has a narrow therapeutic window

Delivery: Achieving sustained CNS concentrations

Targeting: Directing CORMs to affected brain regions

Biomarkers: Defining pharmacodynamic endpoints

Metal toxicity: Ruthenium-based CORMs may cause metal accumulation

Clinical trials to watch:

Phase I studies of CORMs in non-CNS indications may provide safety data
Biomarker studies measuring CO levels and HO-1 expression in neurodegenerative patient cohorts

Comparison with Other Gasotransmitter Therapies {#comparison}

CORMs offer unique advantages:

HO-1 induction creates sustained antioxidant response
Direct mitochondrial targeting with CORM-401
Anti-apoptotic effects complement antioxidant actions

Disease Links

[Alzheimer's Disease](/diseases/alzheimers-disease) — primary indication
[Parkinson's Disease](/diseases/parkinsons-disease) — mitochondrial targeting
[Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis) — motor neuron protection
[Huntington's Disease](/diseases/huntingtons-disease) — transcriptional regulation

Mechanism Links

[Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction-neurodegeneration) — primary target
[Neuroinflammation](/mechanisms/neuroinflammation) — anti-inflammatory effects
[Oxidative Stress](/mechanisms/oxidative-stress-neurodegeneration) — antioxidant effects
[Protein Aggregation](/mechanisms/protein-aggregation-mechanisms) — anti-aggregation effects

Gasotransmitter Links

[Gasotransmitters in Neuroprotection](/mechanisms/gasotransmitters-neuroprotection) — comprehensive gasotransmitter overview
[H2S Donor Therapy](/therapeutics/h2s-donor-therapy-neurodegeneration) — related gasotransmitter therapy
[Nitric Oxide Signaling](/mechanisms/nitric-oxide-signaling-neurodegeneration) — third gasotransmitter

Enzyme/Protein Links

[HO-1 (Heme Oxygenase-1)](/proteins/heme-oxygenase-1) — CO-producing enzyme
[HO-2 (Heme Oxygenase-2)](/proteins/hmox2-protein) — constitutive CO production
[Nrf2](/proteins/nrf2) — antioxidant response regulator

External Links

[PubMed: CO neurodegeneration research](https://pubmed.ncbi.nlm.nih.gov/?term=carbon+monoxide+neurodegeneration)
[HO-1 Gene - NCBI](https://www.ncbi.nlm.nih.gov/gene/3165)
[CORM research papers](https://pubmed.ncbi.nlm.nih.gov/38567890/)

Future Directions {#future-directions}

The field of CORM therapy for neurodegeneration requires:

Improved CORMs: Development of CNS-targeted, sustained-release CORMs with reduced metal toxicity

Combination studies: Evaluation with standard-of-care and disease-modifying therapies

Biomarker development: Identification of CO activity biomarkers for clinical trials

Delivery optimization: Novel formulations (nanoparticles, liposomes) for CNS penetration

Patient selection: Identification of patients with HO-1 deficiency who may benefit most

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — 0.79 · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — 0.76 · Target: ABCA1/LDLR/SREBF2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — 0.75 · Target: TFRC
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7

Related Analyses:

[Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
[Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) 🔄

📖 View canonical wiki page →

carbon-monoxide-therapy-neurodegeneration

Carbon Monoxide (CO) Releasing Compound Therapy for Neurodegeneration

Carbon Monoxide (CO) Releasing Compound Therapy for Neurodegeneration

Overview

The CO Gasotransmitter System {#co-system}

Endogenous CO Production

CO as a Neuroprotective Agent

CO-Releasing Molecule (CORM) Compounds {#corm-compounds}

CORM-2

CORM-3

CORM-401

ALF-494

Neuroprotective Mechanisms {#mechanisms}

Anti-Inflammatory Effects

Anti-Apoptotic Signaling

Antioxidant Effects

Mitochondrial Protection

Autophagy Induction

Therapeutic Applications by Disease {#disease-applications}

Alzheimer's Disease {#alzheimers-disease}

Parkinson's Disease {#parkinsons-disease}

Amyotrophic Lateral Sclerosis {#als}

Huntington's Disease {#huntingtons-disease}

Clinical Development Status {#clinical-status}

Comparison with Other Gasotransmitter Therapies {#comparison}

Cross-Linking and Related Pages {#cross-linking}

Disease Links

Mechanism Links

Gasotransmitter Links

Enzyme/Protein Links

External Links

Future Directions {#future-directions}

Related Hypotheses